CA2910530A1 - New drug for the treatment and/or prevention of depressive disorders - Google Patents

New drug for the treatment and/or prevention of depressive disorders

Info

Publication number
CA2910530A1
CA2910530A1 CA2910530A CA2910530A CA2910530A1 CA 2910530 A1 CA2910530 A1 CA 2910530A1 CA 2910530 A CA2910530 A CA 2910530A CA 2910530 A CA2910530 A CA 2910530A CA 2910530 A1 CA2910530 A1 CA 2910530A1
Authority
CA
Canada
Prior art keywords
compound
treatment
drug
prevention
reuptake inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2910530A
Other languages
English (en)
French (fr)
Inventor
Jean-Jacques Benoliel
Christel Becker
Elodie Bouvier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Universite Paris Descartes
Sorbonne Universite
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Pierre et Marie Curie
Assistance Publique Hopitaux de Paris APHP
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris APHP, Universite Paris Descartes filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA2910530A1 publication Critical patent/CA2910530A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2910530A 2013-05-30 2014-05-30 New drug for the treatment and/or prevention of depressive disorders Abandoned CA2910530A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13169936.5A EP2808023A1 (en) 2013-05-30 2013-05-30 New drug for the treatment and/or prevention of depressive disorders
EP13169936.5 2013-05-30
PCT/EP2014/061240 WO2014191547A1 (en) 2013-05-30 2014-05-30 New drug for the treatment and/or prevention of depressive disorders

Publications (1)

Publication Number Publication Date
CA2910530A1 true CA2910530A1 (en) 2014-12-04

Family

ID=48520808

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2910530A Abandoned CA2910530A1 (en) 2013-05-30 2014-05-30 New drug for the treatment and/or prevention of depressive disorders

Country Status (5)

Country Link
US (2) US20160067231A1 (https=)
EP (2) EP2808023A1 (https=)
JP (1) JP6415545B2 (https=)
CA (1) CA2910530A1 (https=)
WO (1) WO2014191547A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6715568B2 (ja) * 2015-01-22 2020-07-01 公益財団法人東京都医学総合研究所 睡眠異常をきたすうつ病のモデル動物
TWI752282B (zh) * 2017-11-22 2022-01-11 林潔欣 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途
CN116870180B (zh) * 2023-08-08 2026-04-21 中南大学湘雅医院 一种递送神经递质的纳米制剂及其制备方法与应用
CN117904008B (zh) * 2024-03-19 2024-06-11 山东中科嘉亿生物工程有限公司 一种预防和缓解抑郁的戊糖片球菌jypr-9187及其菌剂和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030352A1 (en) * 1999-10-28 2001-05-03 Cary Pharmaceuticals Inc. High dose folic acid for the treatment of hyperhomocysteinemia
US7758872B1 (en) * 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
ATE348818T1 (de) * 2003-06-12 2007-01-15 Btg Int Ltd Cyclische hydroxylamine als psychoactive verbindugen
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
US8969417B2 (en) * 2008-06-06 2015-03-03 Pharmatwob Ltd. Pharmaceutical compositions for treatment of Parkinsons disease
US8778969B2 (en) 2009-11-07 2014-07-15 Peter H Proctor Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines

Also Published As

Publication number Publication date
US20190060298A1 (en) 2019-02-28
EP3003308B1 (en) 2020-09-30
WO2014191547A1 (en) 2014-12-04
JP6415545B2 (ja) 2018-10-31
EP2808023A1 (en) 2014-12-03
JP2016520112A (ja) 2016-07-11
EP3003308A1 (en) 2016-04-13
US20160067231A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
Cao et al. Increased calpain-1 in mitochondria induces dilated heart failure in mice: role of mitochondrial superoxide anion
Okur et al. Long‐term NAD+ supplementation prevents the progression of age‐related hearing loss in mice
US20190060298A1 (en) New drug for the treatment and/or prevention of depressive disorders
Huang et al. Pantothenate kinase 2 interacts with PINK1 to regulate mitochondrial quality control via acetyl-CoA metabolism
Regiane Joca et al. Atypical neurotransmitters and the neurobiology of depression
JP2025114630A (ja) 遺伝性ニューロパチーおよび関連障害の処置および検出
Luo et al. The dual‐functional memantine nitrate MN‐08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models
WO2013039956A2 (en) Compositions and methods for treating mood disorders
Liu et al. Suppression of nuclear factor erythroid 2-related factor 2 via extracellular signal-regulated kinase contributes to bleomycin-induced oxidative stress and fibrogenesis
US20100150944A1 (en) Methods and compositions for diagnosis and treatment of depression and anxiety
Liu et al. Kudiezi injection mitigates myocardial injury induced by acute cerebral ischemia in rats
US20220233443A1 (en) Production and use of extracellular vesicle-contained enampt
WO2000057871A2 (en) Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
He et al. BNTA attenuates temporomandibular joint osteoarthritis progression by directly targeting ALDH3A1: an in vivo and in vitro study
Jung et al. Ethanol withdrawal hastens the aging of cytochrome c oxidase
JP5362747B2 (ja) アルツハイマー病の治療用医薬品の調製のためのｓ−アデノシルメチオニン（ｓａｍ）およびスーパーオキシドジスムターゼ（ｓｏｄ）の使用
US20050169903A1 (en) Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
US12472189B2 (en) Treatment and prevention of capillary malformation-arteriovenous malformation
JP7525591B2 (ja) 心機能不全を予測及び処置するための方法
Huang et al. Preservative-free latanoprost induces meibomian gland dysfunction through inflammatory and oxidative stress pathways
Li et al. Ubiquitin-specific protease 15 reverses the protective effects of sevoflurane on cerebral ischemia-reperfusion injury in mice by deubiquitinating transforming growth factor-βR1
Huo et al. Delta Opioid Peptide [d-Ala2, d-Leu5]-Enkephalin Improves Physical and Cognitive Function and Increases Lifespan in Aged Female Mice
Cavarocchi Genetics and pathophysiology of human asthenozoospermia: identification and functional characterization of IQCH
FLORES GUTIÉRREZ Mirtazapine for Rett syndrome: a candidate to improve quality of life
KR20220064798A (ko) 다낭성 신장질환 치료제 및 이의 스크리닝 방법

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190523

FZDE Discontinued

Effective date: 20220620